Novel Peptide Shows Promise in Reversing Sjögren's Disease Autoimmunity in Mice
Background
Primary Sjögren's disease (pSS) is a chronic, systemic autoimmune disorder primarily affecting exocrine glands, leading to debilitating dry eyes and mouth. Its pathophysiology involves complex interactions, with epithelial cell activation in affected glands playing a crucial role in initiating and perpetuating the autoimmune response. Despite current symptomatic treatments, there remains a significant unmet need for therapies that target the underlying disease mechanisms and halt disease progression. This study sought to investigate whether modulating epithelial activation could mitigate systemic autoimmunity in a preclinical model of pSS.
Results
Treatment with EpithelioModulin-1 (EM-1) significantly improved salivary gland function and reduced inflammatory markers. The high-dose EM-1 group exhibited a 43% increase in stimulated saliva flow compared to the vehicle group (p<0.001), while the low-dose group showed a 28% increase (p<0.01). Histological analysis revealed a 65% reduction in lymphocytic infiltration scores in the salivary glands of high-dose EM-1 treated mice (p<0.001), indicating a substantial decrease in local inflammation. Furthermore, systemic markers of autoimmunity were also positively impacted. > The most striking finding was a 2.5-fold decrease in circulating anti-Ro/SSA autoantibody levels in the high-dose EM-1 group compared to controls (p<0.0001), suggesting a broad systemic immunomodulatory effect. Additionally, IFN-gamma and IL-6 cytokine levels in salivary gland tissue were reduced by 58% and 51% respectively in the high-dose group (p<0.001 for both), confirming a direct impact on epithelial-driven inflammation.
Why It Matters
This study provides compelling evidence that targeting epithelial cell activation with EpithelioModulin-1 (EM-1) can effectively mitigate both local glandular inflammation and systemic autoimmunity in a preclinical model of Sjögren's disease. The significant reduction in autoantibody levels and improvement in salivary function highlight EM-1's potential as a disease-modifying therapy. This research suggests a promising new therapeutic avenue for Sjögren's disease patients, moving beyond symptomatic relief to address the root causes of the disease. These findings strongly support further development of EM-1, potentially leading to human clinical trials (Phase I/II) to evaluate its safety and efficacy in patients with pSS.